

FUND DESCRIPTION

“Where health care meets technology”

Companies within this fund are focused on, and are expected to benefit from, extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements, and advancements in genomics into their business.

INVESTMENT OBJECTIVE

This actively managed fund seeks to achieve long-term growth of capital by investing primarily, under normal circumstances, in global equity securities of companies that are, or are expected to be, focused on extending and enhancing the quality of human and other life through technological and scientific developments, improvements, and advancements in genomics.

WHY INVEST?

1. Exposure to innovation

Aims for thematic multi-cap exposure to innovative technologies, including: health care revolution, biotechnology, genomic advancements, and DNA sequencing.

2. Growth potential

Aims to capture long-term growth with a low correlation of relative returns to traditional growth strategies and negative correlation to value strategies.

3. Tool for diversification

Offers a tool for diversification due to little overlap with traditional indices. It can be a complement to traditional value/ growth strategies.

4. Grounded in research

Combines top-down and bottom-up research in its portfolio management to identify innovative companies and convergence across markets.

FUND DETAILS
AS AT 29.10.21

Series	A, F, O
Type	Equity Sector Weights
Currency	CAD/USD
Inception date	04.10.2021 ¹
Sales Charge	1.0% ²
Commission Fee	Up to 5%
Management Fee	1.80%
Min. Investment (\$)	Based on fund series type ³
Typical number of holdings	35-50
Portfolio manager	Emerge Canada Inc.
Sub-advisers	ARK Investment Management LLC Emerge Capital Management Inc. ⁴

TOP 10 HOLDINGS
AS AT 29.10.21

Teladoc Health, Inc.	9.1%
Pacific Biosciences Of California, Inc.	5.3%
Exact Sciences Corporation	5.1%
Ionis Pharmaceuticals, Inc.	3.8%
Vertex Pharmaceuticals Incorporated	3.8%
Twist Bioscience Corporation	3.6%
Fate Therapeutics, Inc.	3.5%
Intellia Therapeutics, Inc.	3.2%
Accolade, Inc.	3.1%
Ginkgo Bioworks Holdings, Inc.	3.0%

SECTOR WEIGHTS
AS AT 29.10.21

Healthcare	96.5%
Information Technology	2.7%
Financials	0.3%

GEOGRAPHIC ALLOCATION
AS AT 29.10.21

Americas	93.2%
Asia	3.3%
Europe	2.6%
Middle-East	0.4%

FUND CODES AND TICKER

	TICKER	CAD CODE	USD CODE
SERIES A	EAGBA	ECI200	ECI201
SERIES F	EAGBF	ECI210	ECI211
SERIES O	EAGBO	ECI220	ECI221



PORTFOLIO MANAGER (SUB-ADVISOR)

Catherine D. Wood

Chief Investment Officer

ARK Investment Management LLC

Catherine registered ARK Investment Management LLC (“ARK”) as an investment adviser with the U.S. Securities and Exchange Commission in January 2014. With over 40 years of experience identifying and investing in innovation, Catherine founded ARK to focus solely on disruptive innovation while adding new dimensions to research. Previously, she completed twelve years at AllianceBernstein as Chief Investment Officer of Global Thematic Strategies with over \$5 billion in assets under management. Before AllianceBernstein, she worked for eighteen years with Jennison Associates as Chief Economist, Equity Research Analyst, Portfolio Manager, and Director. Catherine started her career in Los Angeles at the Capital Group as an Assistant Economist.

